This classifier was further tested in ICI-treated cohorts including hormone receptor (HR)-positive/HER2-negative breast cancer (BC) patients, other immune hot and cold non-BC solid tumors (bladder, esophageal, melanoma, and renal), and in an ICI-naïve cohort of patients with TNBC treated with chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.